A biotechnology company developing innovative product candidates, including new and existing drugs, applicable to a range of diseases where purine metabolism disorders and elevated uric acid are common denominators, with a focus on identifying, developing and commercializing therapies for autosomal dominant polycystic kidney disease, type 2 diabetic nephropathy, respiratory viral infection-associated AKI and progressive kidney disease.